secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001161697-23-000441
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q2 revenue $6.9M (+6% YoY); cuts FY2023 revenue guidance to $31.0-32.5M
--------------------------------------------------------------------------------

- Q2 net revenue $6.9M (+6% YoY); Domestic Core +8%, International Core +17%.
- Net loss $2.5M ($0.05/sh) improved from $2.9M loss ($0.07/sh) prior year; gross margin 56.1%.
- Cuts FY2023 revenue guidance to $31.0-32.5M (11-17% growth) from prior $32.5-33.5M (17-20% growth).
- Appoints Tom Adams as CFO; submitted 510(k) for FREEDOM60 with Hizentra prefilled syringes.
- Reaffirms FY2023 gross margin 58-60% and year-end cash >$10.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-23-000441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer